Return to Today's science sparks archives

2018-01-02

Fig 1. Extrathyroidal extension (ETE). A,B, Gross ETE: a patient with papillary thyroid carcinoma (PTC) with pre-operative radiological evidence of invasion into trachea. Macroscopically (A), an infiltrative firm beige mass was present involving thyroid gland proper and infiltrating between tracheal rings (T). Microscopically, the carcinoma infiltrated in between tracheal cartilage and was present at the tracheal mucosal surface. This tumour should be staged as pT4a based on gross ETE into trachea. C,D, Microscopic (minimal) ETE: tumour nests were present in between perithyroidal adipose tissue (FAT, panel C) or skeletal muscle (M, panel D).

Fig 1. Extrathyroidal extension (ETE). A,B, Gross ETE: a patient with papillary thyroid carcinoma (PTC) with pre-operative radiological evidence of invasion into trachea. Macroscopically (A), an infiltrative firm beige mass was present involving thyroid gland proper and infiltrating between tracheal rings (T). Microscopically, the carcinoma infiltrated in between tracheal cartilage and was present at the tracheal mucosal surface. This tumour should be staged as pT4a based on gross ETE into trachea. C,D, Microscopic (minimal) ETE: tumour nests were present in between perithyroidal adipose tissue (FAT, panel C) or skeletal muscle (M, panel D).
  • Xu B, Ghossein RA

  • Histopathology. 2018 Jan;72(1):32-39.

2018-01-03

Fig 3. (A) Photon flux enhancement of 89Zr through the combination with E8 gels at various concentrations. (B) Photon counts of E8 gels having different E8 gelator concentrations in the presence of the 89Zr radionuclide.

Fig 3. (A) Photon flux enhancement of 89Zr through the combination with E8 gels at various concentrations. (B) Photon counts of E8 gels having different E8 gelator concentrations in the presence of the 89Zr radionuclide.
  • Silverman JR, Zhang Q, Pramanik NB, Samateh M, Shaffer TM, Sagiri SS, Grimm J, John G

  • ACS Appl Mater Interfaces. 2017 Dec 13;9(49):43197-43204.

2018-01-04

Fig 4. Distribution of kinase fusions across primary tumour sites.

Fig 4. Distribution of kinase fusions across primary tumour sites.
  • Schram AM, Chang MT, Jonsson P, Drilon A

  • Nat Rev Clin Oncol. 2017 Dec;14(12):735-748.

2018-01-05

Fig 2. Kaplan-Meier curves of (A and B) overall survival (OS) and (C and D) progression-free survival

Fig 2. Kaplan-Meier curves of (A and B) overall survival (OS) and (C and D) progression-free survival
  • Horn L, Spigel DR, Vokes EE, Holgado E, Ready N, Steins M, Poddubskaya E, Borghaei H, Felip E, Paz-Ares L, Pluzanski A, Reckamp KL, Burgio MA, Kohlhäeufl M, Waterhouse D, Barlesi F, Antonia S, Arrieta O, Fayette J, Crinò L, Rizvi N, Reck M, Hellmann MD, Geese WJ, Li A, Blackwood-Chirchir A, Healey D, Brahmer J, Eberhardt WEE

  • J Clin Oncol. 2017 Dec 10;35(35):3924-3933.

2018-01-08

Fig 1. Two overlapping connectivity envelopes surround the patient.

Fig 1. Two overlapping connectivity envelopes surround the patient.
  • Anderson DC, Jackson AA, Halpern NA

  • Crit Care Nurs Q. 2018 Jan/Mar;41(1):60-67.

2018-01-09

Figure 1. Cavity in the BPTI protein, with waters A, B, and C bound.

Figure 1. Cavity in the BPTI protein, with waters A, B, and C bound.
  • Ross GA, Bruce Macdonald HE, Cave-Ayland C, Cabedo Martinez AI, Essex JW

  • J Chem Theory Comput. 2017 Dec 12;13(12):6373-6381.
Open Access button

2018-01-10

Figure 1. Plasma concentration of ASP8273 in patients in the dose escalation cohorts after a single dose of ASP8273.

Figure 1. Plasma concentration of ASP8273 in patients in the dose escalation cohorts after a single dose of ASP8273.
  • Yu HA, Spira A, Horn L, Weiss J, West H, Giaccone G, Evans T, Kelly RJ, Desai B, Krivoshik A, Moran D, Poondru S, Jie F, Aoyama K, Keating A, Oxnard GR

  • Clin Cancer Res. 2017 Dec 15;23(24):7467-7473.

2018-01-11

Fig 5. Example of separation surgery followed by stereotactic spine radiotherapy in a patient with spinal cord compression.

Fig 5. Example of separation surgery followed by stereotactic spine radiotherapy in a patient with spinal cord compression.
  • Spratt DE, Beeler WH, de Moraes FY, Rhines LD, Gemmete JJ, Chaudhary N, Shultz DB, Smith SR, Berlin A, Dahele M, Slotman BJ

  • Lancet Oncol. 2017 Dec;18(12):e720-e730.

2018-01-12

Figure 5.  Clinical response to mIDH2 inhibition is associated with induction of myeloid differentiation.

Figure 5.  Clinical response to mIDH2 inhibition is associated with induction of myeloid differentiation.
  • Stein EM

  • Future Oncol. 2018 Jan;14(1):23-40.

2018-01-15

Fig 1. Regulation of ferroptosis by cellular metabolism.

Fig 1. Regulation of ferroptosis by cellular metabolism.
  • Gao M, Jiang X

  • Curr Opin Cell Biol. 2017 Nov 22;51:58-64.

2018-01-16

Figure 6. Near complete penetration of the Cre-recombinase in PdxCre;R26DTR/mTmG mice.

Figure 6. Near complete penetration of the Cre-recombinase in PdxCre;R26DTR/mTmG mice.
  • Socorro M, Criscimanna A, Riva P, Tandon M, Prasadan K, Guo P, Humar A, Husain SZ, Leach SD, Gittes GK, Esni F

  • Sci Rep. 2017 Dec 13;7(1):17539.
Open Access button

2018-01-17

Fig. 4. Defects in mesoderm migration in Strip1 mutant embryos.

Fig. 4. Defects in mesoderm migration in Strip1 mutant embryos.
  • Bazzi H, Soroka E, Alcorn HL, Anderson KV

  • Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10928-E10936.
Open Access button

2018-01-18

Fig 1. Treatment algorithm for non-muscle invasive bladder cancer.

Fig 1. Treatment algorithm for non-muscle invasive bladder cancer.
  • Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O’Donnell MA, O’Donnell PH, Petrylak DP

  • J Immunother Cancer. 2017 Aug 15;5(1):68.
Open Access button

2018-01-19

Figure 1. Design concept of folate-assisted on target drug delivery.

Figure 1. Design concept of folate-assisted on target drug delivery.
  • Roti G, Qi J, Kitara S, Sanchez-Martin M, Saur Conway A, Varca AC, Su A, Wu L, Kung AL, Ferrando AA, Bradner JE, Stegmaier K

  • J Exp Med. 2018 Jan 2;215(1):197-216.

2018-01-22

Figure 2. Docking of saccharin-based inhibitors into the active site of the rhomboid protease GlpG.

Figure 2. Docking of saccharin-based inhibitors into the active site of the rhomboid protease GlpG.
  • Goel P, Jumpertz T, Mikles DC, Tichá A, Nguyen MTN, Verhelst S, Hubalek M, Johnson DC, Bachovchin DA, Ogorek I, Pietrzik CU, Strisovsky K, Schmidt B, Weggen S

  • Biochemistry. 2017 Dec 26;56(51):6713-6725.

2018-01-23

Figure 1. Shutting down stem and memory genes in CD8+ T cells.

Figure 1. Shutting down stem and memory genes in CD8+ T cells.
  • Henning AN, Klebanoff CA, Restifo NP

  • Science. 2018 Jan 12;359(6372):163-164.

2018-01-24

Figure 6. Akt3/−S472 enhances EGF-stimulated EGFR endocytosis.

Figure 6. Akt3/−S472 enhances EGF-stimulated EGFR endocytosis.
  • Suyama K, Yao J, Liang H, Benard O, Loudig OD, Amgalan D, McKimpson WM, Phillips GR, Segall J, Wang Y, Fineberg S, Norton L, Kitsis RN, Hazan RB

  • Cancer Res. 2018 Jan 1;78(1):103-114.

2018-01-26

FIG. 1. Treatment with SRS to a previously cement-augmented vertebra.

FIG. 1. Treatment with SRS to a previously cement-augmented vertebra.
  • Barzilai O, DiStefano N, Lis E, Yamada Y, Lovelock DM, Fontanella AN, Bilsky MH, Laufer I

  • J Neurosurg Spine. 2018 Jan;28(1):72-78.

2018-01-29

Figure 1.Schematic representation of NK-cell functions in neuroblastoma (NB).

Figure 1.Schematic representation of NK-cell functions in neuroblastoma (NB).
  • Cheung NK, Hsu KC

  • Clin Cancer Res. 2018 Jan 1;24(1):3-5.

2018-01-30

Figure 3. Interactions with the guanine nucleobase, GDP phosphates, and magnesium.

Figure 3. Interactions with the guanine nucleobase, GDP phosphates, and magnesium.
  • Remus BS, Goldgur Y, Shuman S

  • Nucleic Acids Res. 2017 Dec 15;45(22):12945-12953.
Open Access button

2018-01-31

Figure 1. Significance of selecting NP.

Figure 1. Significance of selecting NP.
  • Han S, Stoyanova R, Lee H, Carlin SD, Koutcher JA, Cho H, Ackerstaff E

  • Magn Reson Med. 2018 Mar;79(3):1736-1744.

2018-02-01

Fig 1. Bi-allelic pathogenic alterations affecting HR-related genes affect multiple cancer types and are associated with genomics features of HR deficiency.

Fig 1. Bi-allelic pathogenic alterations affecting HR-related genes affect multiple cancer types and are associated with genomics features of HR deficiency.
  • Riaz N, Blecua P, Lim RS, Shen R, Higginson DS, Weinhold N, Norton L, Weigelt B, Powell SN, Reis-Filho JS

  • Nat Commun. 2017 Oct 11;8(1):857.
Open Access button

2018-02-02

Fig 2. Postoperative radiotherapy plans for a patient with salivary duct carcinoma of the left accessory parotid gland.

Fig 2. Postoperative radiotherapy plans for a patient with salivary duct carcinoma of the left accessory parotid gland.
  • Leeman JE, Romesser PB, Zhou Y, McBride S, Riaz N, Sherman E, Cohen MA, Cahlon O, Lee N

  • Lancet Oncol. 2017 May;18(5):e254-e265.

2018-02-05

Figure 1. Acceptance of treatment for latent tuberculosis infection by year of diagnosis.

Figure 1. Acceptance of treatment for latent tuberculosis infection by year of diagnosis.
  • Arguello Perez E, Seo SK, Schneider WJ, Eisenstein C, Brown AE

  • Clin Infect Dis. 2017 Nov 29;65(12):2105-2111.

2018-02-06

FIG. 1. Significance of selecting NP.

FIG. 1. Significance of selecting NP.
  • Han S, Stoyanova R, Lee H, Carlin SD, Koutcher JA, Cho H, Ackerstaff E

  • Magn Reson Med. 2018 Mar;79(3):1736-1744.

2018-02-07

Figure 2. Cellular stress can trigger astrogliosis—increased numbers of reactive astrocytes.

Figure 2. Cellular stress can trigger astrogliosis—increased numbers of reactive astrocytes.
  • Frost GR, Li YM

  • Open Biol. 2017 Dec;7(12). pii: 170228.
Open Access button

2018-02-08

Fig. 1. Kaplan-Meier survival analysis.

Fig. 1. Kaplan-Meier survival analysis.
  • Getta BM, Devlin S, Park JH, Tallman MS, Berman E

  • Leuk Res. 2018 Jan 3;65:80-85.

2018-02-09

Figure 1. A sample workflow for informatics in cancer immunotherapy.

Figure 1. A sample workflow for informatics in cancer immunotherapy.
  • Hammerbacher J, Snyder A

  • Ann Oncol. 2017 Dec 1;28(suppl_12):xii56-xii73.

2018-02-12

Figure 2. Initial grade 2 rash (not shown) with combination therapy progressing to grade 3 rash with anti-programmed death 1 (PD-1)rechallenge.

Figure 2. Initial grade 2 rash (not shown) with combination therapy progressing to grade 3 rash with anti-programmed death 1 (PD-1)rechallenge.
  • Pollack MH, Betof A, Dearden H, Rapazzo K, Valentine I, Brohl AS, Ancell KK, Long GV, Menzies AM, Eroglu Z, Johnson DB, Shoushtari AN

  • Ann Oncol. 2018 Jan 1;29(1):250-255.

2018-02-13

Fig 5: Heat map combined with regression analysis of metabolism-related pathways for the 20 MSKCC Director’s Challenge samples of lung adenocarcinoma with available PET SUV data.

Fig 5: Heat map combined with regression analysis of metabolism-related pathways for the 20 MSKCC Director’s Challenge samples of lung adenocarcinoma with available PET SUV data.
  • Riester M, Xu Q, Moreira A, Zheng J, Michor F, Downey RJ

  • Ann Oncol. 2018 Jan 1;29(1):264-270.

2018-02-14

Fig. 1.1: SV40 and cellular DNA replication.

Fig. 1.1: SV40 and cellular DNA replication.
  • Kelly, T

  • Adv Exp Med Biol. 2017;1042:1-41.

2018-02-15

Fig. 1. Clinical outcomes by National Comprehensive Cancer Network risk group for (A) prostate-specific antigen (PSA) recurrence–free survival, (B) distant metastasis–free survival, (C) overall survival, and (D) and cancer-specific survival. Abbreviation: RT = radiation therapy.

Fig. 1. Clinical outcomes by National Comprehensive Cancer Network risk group for (A) prostate-specific antigen (PSA) recurrence–free survival, (B) distant metastasis–free survival, (C) overall survival, and (D) and cancer-specific survival. Abbreviation: RT = radiation therapy.
  • Romesser PB, Pei X, Shi W, Zhang Z, Kollmeier M, McBride SM, Zelefsky MJ

  • Int J Radiat Oncol Biol Phys. 2018 Jan 1;100(1):59-67.

2018-02-16

Fig 2: Interactions with
AdoHcy (sticks with cyan carbon atoms).

Fig 2: Interactions with AdoHcy (sticks with cyan carbon atoms).
  • Diver MM, Pedi L, Koide A, Koide S, Long SB

  • Nature. 2018 Jan 25;553(7689):526-529.

2018-02-19

Figure 1. Scanning electron micrograph of chimeric antigen
receptor T cells pseudocolored (green) attacking a cultured
mesothelin-overexpressing malignant mesothelioma cell.

Figure 1. Scanning electron micrograph of chimeric antigen receptor T cells pseudocolored (green) attacking a cultured mesothelin-overexpressing malignant mesothelioma cell.
  • Kiesgen S, Chicaybam L, Chintala NK, Adusumilli PS

  • J Thorac Oncol. 2018 Jan;13(1):16-26.

2018-02-20

Fig 1. Hedvig Hricak, Memorial Sloan Kettering Cancer Center.

Fig 1. Hedvig Hricak, Memorial Sloan Kettering Cancer Center.
  • Wibmer AG, Vargas HA, Hricak H

  • Nat Rev Urol. 2018 Feb;15(2):81-82.

2018-02-21

Fig. 1—67-year-old man with newly diagnosed occlusive cancer in descending colon.

Fig. 1—67-year-old man with newly diagnosed occlusive cancer in descending colon.
  • Horvat N, Raj A, Ward JM, Smith JJ, Markowitz AJ, Gollub MJ

  • AJR Am J Roentgenol. 2018 Feb;210(2):333-340.

2018-02-22

Fig. 4. TP63 abnormal RT is not dependent on progerin expression and is observed in other progeroid syndromes.

Fig. 4. TP63 abnormal RT is not dependent on progerin expression and is observed in other progeroid syndromes.
  • Rivera-Mulia JC, Desprat R, Trevilla-Garcia C, Cornacchia D, Schwerer H, Sasaki T, Sima J, Fells T, Studer L, Lemaitre JM, Gilbert DM

  • Proc Natl Acad Sci U S A. 2017 Dec 19;114(51):E10972-E10980.

2018-02-23

Fig. 5: MDA-MB-231 cells
stained using DAPI, anti-dsDNA antibody,
or mCherry–lamin B2 (arrow).

Fig. 5: MDA-MB-231 cells stained using DAPI, anti-dsDNA antibody, or mCherry–lamin B2 (arrow).
  • Bakhoum SF, Ngo B, Laughney AM, Cavallo JA, Murphy CJ, Ly P, Shah P, Sriram RK, Watkins TBK, Taunk NK, Duran M, Pauli C, Shaw C, Chadalavada K, Rajasekhar VK, Genovese G, Venkatesan S, Birkbak NJ, McGranahan N, Lundquist M, LaPlant Q, Healey JH, Elemento O, Chung CH, Lee NY, Imielenski M, Nanjangud G, Pe'er D, Cleveland DW, Powell SN, Lammerding J, Swanton C, Cantley LC

  • Nature. 2018 Jan 25;553(7689):467-472.

2018-02-26

Fig 3. PPP1R1A promotes cell migration and tumor metastasis in ES.

Fig 3. PPP1R1A promotes cell migration and tumor metastasis in ES.
  • Luo W, Xu C, Ayello J, Dela Cruz F, Rosenblum JM, Lessnick SL, Cairo MS

  • Oncogene. 2018 Feb 8;37(6):798-809.

2018-02-27

Fig. 1. HET-C2 Trp locations compared to GLTP.

Fig. 1. HET-C2 Trp locations compared to GLTP.
  • Kenoth R, Zou X, Simanshu DK, Pike HM, Malinina L, Patel DJ, Brown RE, Kamlekar RK

  • Biochim Biophys Acta. 2018 Jan 3;1860(5):1069-1076.

2018-02-28

Fig 2. An example of a BREAST-Q result for a patient who underwent breast reconstruction.

Fig 2. An example of a BREAST-Q result for a patient who underwent breast reconstruction.
  • Voineskos SH, Nelson JA, Klassen AF, Pusic AL

  • Annu Rev Med. 2018 Jan 29;69:467-479.

2018-03-01

Figure 5. Harmine leads to degradation of the E2A proteins, which are required for suppression of OIS.

Figure 5. Harmine leads to degradation of the E2A proteins, which are required for suppression of OIS.
  • Yochum ZA, Cades J, Mazzacurati L, Neumann NM, Khetarpal SK, Chatterjee S, Wang H, Attar MA, Huang EH, Chatley SN, Nugent K, Somasundaram A, Engh JA, Ewald AJ, Cho YJ, Rudin CM, Tran PT, Burns TF

  • Mol Cancer Res. 2017 Dec;15(12):1764-1776.

2018-03-02

Fig 1. Elements of the ImmunoMap algorithm.

Fig 1. Elements of the ImmunoMap algorithm.
  • Sidhom JW, Bessell CA, Havel JJ, Kosmides A, Chan TA, Schneck JP

  • Cancer Immunol Res. 2018 Feb;6(2):151-162.

2018-03-05

FIG 1.Path diagram of hypothesized medication model of the effect of Meaning-Centered Group Psychotherapy (MCGP) on patients’ outcomes.

FIG 1.Path diagram of hypothesized medication model of the effect of Meaning-Centered Group Psychotherapy (MCGP) on patients’ outcomes.
  • Rosenfeld B, Cham H, Pessin H, Breitbart W

  • Psychooncology. 2018 Feb;27(2):654-660.
Open Access button

2018-03-06

Fig. 17.1: Summary of main steps of DNA replication initiation in budding yeast.

Fig. 17.1: Summary of main steps of DNA replication initiation in budding yeast.
  • Wei L, Zhao X

  • Adv Exp Med Biol. 2017;1042:371-393.

2018-03-07

Fig 2. Integrated efficacy by tumour type and HER2 allele/domain.

Fig 2. Integrated efficacy by tumour type and HER2 allele/domain.
  • Hyman DM, Piha-Paul SA, Won H, Rodon J, Saura C, Shapiro GI, Juric D, Quinn DI, Moreno V, Doger B, Mayer IA, Boni V, Calvo E, Loi S, Lockhart AC, Erinjeri JP, Scaltriti M, Ulaner GA, Patel J, Tang J, Beer H, Selcuklu SD, Hanrahan AJ, Bouvier N, Melcer M, Murali R, Schram AM, Smyth LM, Jhaveri K, Li BT, Drilon A, Harding JJ, Iyer G, Taylor BS, Berger MF, Cutler RE Jr, Xu F, Butturini A, Eli LD, Mann G, Farrell C, Lalani AS, Bryce RP, Arteaga CL, Meric-Bernstam F, Baselga J, Solit DB

  • Nature. 2018 Feb 8;554(7691):189-194.

2018-03-08

Fig. 1. Post-IND1 hepatotoxicity in patients who completed at least IND2 and had post-IND1 hepatotoxicity.

Fig. 1. Post-IND1 hepatotoxicity in patients who completed at least IND2 and had post-IND1 hepatotoxicity.
  • Burke PW, Aldoss I, Lunning MA, Devlin SM, Tallman MS, Pullarkat V, Mohrbacher AM, Douer D

  • Leuk Res. 2018 Jan 3;66:49-56.

2018-03-09

Fig 2. An array of salvage regimens for RRMM comprising proteasome inhibitor (PI), immunomodulatory agents (IMiD), anti-CD38(daratumumab [Dara]) or anti-SLAMF7 (elotuzumab [Elo]) monoclonal antibodies, BCL2 inhibitor (BCL2i), exportin-1 inhibitor (XPO1-i), anti-PD1 check-point inhibitors or CAR-T cells.

Fig 2. An array of salvage regimens for RRMM comprising proteasome inhibitor (PI), immunomodulatory agents (IMiD), anti-CD38(daratumumab [Dara]) or anti-SLAMF7 (elotuzumab [Elo]) monoclonal antibodies, BCL2 inhibitor (BCL2i), exportin-1 inhibitor (XPO1-i), anti-PD1 check-point inhibitors or CAR-T cells.
  • Chim CS, Kumar SK, Orlowski RZ, Cook G, Richardson PG, Gertz MA, Giralt S, Mateos MV, Leleu X, Anderson KC

  • Leukemia. 2018 Feb;32(2):252-262.

2018-03-13

Fig. 6. FA proteins regulate recruitment of DSB repair proteins to sites of replication-associated DNA damage in U2OS cells.

Fig. 6. FA proteins regulate recruitment of DSB repair proteins to sites of replication-associated DNA damage in U2OS cells.
  • Eccles LJ, Bell AC, Powell SN

  • DNA Repair (Amst). 2018 Feb 10;64:1-9.

2018-03-14

Fig. 1 Regulation of mTORC1 and nutrient-scavenging pathwaysby TM9SF4.

Fig. 1 Regulation of mTORC1 and nutrient-scavenging pathwaysby TM9SF4.
  • Fais S, Overholtzer M

  • Cell Death Dis. 2018 Jan 24;9(2):95.

2018-03-15

Figure 1: Timeline of key developments in therapeutically targeting RET in the clinic.

Figure 1: Timeline of key developments in therapeutically targeting RET in the clinic.
  • Drilon A, Hu ZI, Lai GGY, Tan DSW

  • Nat Rev Clin Oncol. 2018 Mar;15(3):151-167.

2018-03-16

Figure 1. Flow diagram. *Numbers do not add up to 373 because there is overlap among patients with missing information for each variable. ITMIG, International Thymic Malignancy Interest Group; PN/AI, paraneoplastic/autoimmune syndrome.

Figure 1. Flow diagram. *Numbers do not add up to 373 because there is overlap among patients with missing information for each variable. ITMIG, International Thymic Malignancy Interest Group; PN/AI, paraneoplastic/autoimmune syndrome.
  • Padda SK, Yao X, Antonicelli A, Riess JW, Shang Y, Shrager JB, Korst R, Detterbeck F, Huang J, Burt BM, Wakelee HA, Badve SS

  • J Thorac Oncol. 2018 Mar;13(3):436-446.

2018-03-19

Fig 1: Risk predictions from super leaner analyses for 9,651 patients at risk for: (i) acute GVHD within 100 days, and (ii) the composite endpoint of acute GVHD and death within 100 days.

Fig 1: Risk predictions from super leaner analyses for 9,651 patients at risk for: (i) acute GVHD within 100 days, and (ii) the composite endpoint of acute GVHD and death within 100 days.
  • Lee C, Haneuse S, Wang HL, Rose S, Spellman SR, Verneris M, Hsu KC, Fleischhauer K, Lee SJ, Abdi R

  • PLoS One. 2018 Jan 18;13(1):e0190610.
Open Access button

2018-03-20

Fig 4. Intact TLR3- and IFN-Responsive Pathways, and Very HighRNALariat Levels in DBR1-Deficient Fibroblasts following HSV1 Infection.

Fig 4. Intact TLR3- and IFN-Responsive Pathways, and Very HighRNALariat Levels in DBR1-Deficient Fibroblasts following HSV1 Infection.
  • Zhang SY, Clark NE, Freije CA, Pauwels E, Taggart AJ, Okada S, Mandel H, Garcia P, Ciancanelli MJ, Biran A, Lafaille FG, Tsumura M, Cobat A, Luo J, Volpi S, Zimmer B, Sakata S, Dinis A, Ohara O, Garcia Reino EJ, Dobbs K, Hasek M, Holloway SP, McCammon K, Hussong SA, DeRosa N, Van Skike CE, Katolik A, Lorenzo L, Hyodo M, Faria E, Halwani R, Fukuhara R, Smith GA, Galvan V, Damha MJ, Al-Muhsen S, Itan Y, Boeke JD, Notarangelo LD, Studer L, Kobayashi M, Diogo L, Fairbrother WG, Abel L, Rosenberg BR, Hart PJ, Etzioni A, Casanova JL

  • Cell. 2018 Feb 22;172(5):952-965.e18.

2018-03-21

Fig. 5 Differential diagnoses of hepatosplenic T-cell lymphoma (HSTCL).

Fig. 5 Differential diagnoses of hepatosplenic T-cell lymphoma (HSTCL).
  • Yabe M, Miranda RN, Medeiros LJ

  • Hum Pathol. 2018 Jan 11. pii: S0046-8177(18)30006-6.

2018-03-22

Fig 1. Characterization of four distinct mutational signatures in breast cancer.

Fig 1. Characterization of four distinct mutational signatures in breast cancer.
  • Polak P, Kim J, Braunstein LZ, Karlic R, Haradhavala NJ, Tiao G, Rosebrock D, Livitz D, Kübler K, Mouw KW, Kamburov A

  • Nat Genet. 2017 Oct;49(10):1476-1486.

2018-03-23

Fig 1. Molecular response rates at 3, 6, 9, and 12 months (modified intent-to-treat population).

Fig 1. Molecular response rates at 3, 6, 9, and 12 months (modified intent-to-treat population).
  • Cortes JE, Gambacorti-Passerini C, Deininger MW, Mauro MJ, Chuah C, Kim DW, Dyagil I, Glushko N, Milojkovic D, le Coutre P, Garcia-Gutierrez V, Reilly L, Jeynes-Ellis A, Leip E, Bardy-Bouxin N, Hochhaus A, Brümmendorf TH

  • J Clin Oncol. 2018 Jan 20;36(3):231-237.

2018-03-26

Fig 1. Structures of 5-A-RU (1), the Schiff base it forms with methylglyoxal (5-OP-RU), and the covalent attachment of the latter to MR1.

Fig 1. Structures of 5-A-RU (1), the Schiff base it forms with methylglyoxal (5-OP-RU), and the covalent attachment of the latter to MR1.
  • Li K, Vorkas CK, Chaudhry A, Bell DL, Willis RA, Rudensky A, Altman JD, Glickman MS, Aubé J

  • PLoS One. 2018 Feb 5;13(2):e0191837.
Open Access button

2018-03-27

Fig 1. Remote physical assessment: technologies, sensor modalities, and application domains.

Fig 1. Remote physical assessment: technologies, sensor modalities, and application domains.
  • Fallahzadeh R, Ghasemzadeh H, Shahrokni A

  • Curr Oncol Rep. 2018 Mar 8;20(3):26.

2018-03-28

Fig 3. HPV-positivity in a usual type adenocarcinoma using the ACD RNAscope probe HPV HR18.

Fig 3. HPV-positivity in a usual type adenocarcinoma using the ACD RNAscope probe HPV HR18.
  • Stolnicu S, Barsan I, Hoang L, Patel P, Terinte C, Pesci A, Aviel-Ronen S, Kiyokawa T, Alvarado-Cabrero I, Pike MC, Oliva E, Park KJ, Soslow RA

  • Am J Surg Pathol. 2018 Feb;42(2):214-226.

2018-03-29

Figure 2.  Possible Mechanisms Underlying Immune-Related Adverse Events.

Figure 2. Possible Mechanisms Underlying Immune-Related Adverse Events.
  • Postow MA, Sidlow R, Hellmann MD

  • N Engl J Med. 2018 Jan 11;378(2):158-168.

2018-03-30

Figure 1. Mice from the ENU-induced mutant line ketu have meiotic defects.

Figure 1. Mice from the ENU-induced mutant line ketu have meiotic defects.
  • Jain D, Puno MR, Meydan C, Lailler N, Mason CE, Lima CD, Anderson KV, Keeney S

  • Elife. 2018 Jan 23;7. pii: e30919.
Open Access button